Dr. Jonathan A. Bernstein, MD
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
Medicare and federal program status
Opted out of Medicare from May 20, 2025 through May 20, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated July 15, 2025). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 276
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
OH license 35 053762 -
Internal Medicine Physician
OH license 35 053762
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 276
- Services billed
- 1,343
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 323 | 195 |
| Professional service for multiple injections of allergen | 97 | 17 |
| Test to measure expiratory airflow and volume | 70 | 67 |
| Established patient office or other outpatient visit, 20-29 minutes | 60 | 52 |
| New patient office or other outpatient visit, 45-59 minutes | 37 | 37 |
| Test to measure the level of nitric oxide gas | 20 | 19 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 18 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azelastine Hcl Other prescribers in Cincinnati, OH | 239 |
| Fluticasone Propionate Other prescribers in Cincinnati, OH | 166 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Cincinnati, OH | 157 |
| Famotidine Other prescribers in Cincinnati, OH | 145 |
| Montelukast Sodium Other prescribers in Cincinnati, OH | 145 |
| Ipratropium Bromide Other prescribers in Cincinnati, OH | 87 |
| Prednisone Other prescribers in Cincinnati, OH | 72 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Cincinnati, OH | 67 |
| Omeprazole Other prescribers in Cincinnati, OH | 66 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Cincinnati, OH | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 147 payments worth $100,888 in total to this clinician.
| Csl Behring | $33,268 |
|---|---|
| Novartis Pharmaceuticals Corporation | $17,882 |
| Pharming Healthcare, Inc. | $15,271 |
| Eli Lilly and Company | $10,400 |
| AbbVie Inc. | $8,657 |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,690 |
| Biocryst Pharmaceuticals, Inc. | $4,453 |
| Genzyme Corporation | $3,845 |
| Consulting Fee | $56,392 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $36,722 |
| Travel and Lodging | $5,162 |
| Food and Beverage | $2,592 |
| Education | $19.31 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation May 2, 2025 | Consulting Fee | $10,000 |
| Eli Lilly and Company Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $8,000 |
| Csl Behring Jan 28, 2025 | Consulting Fee Andembry · Hematology | $7,920 |
| AbbVie Inc. Mar 14, 2025 | Consulting Fee | $5,800 |
| Pharming Healthcare, Inc. May 29, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $5,625 |
| Pharming Healthcare, Inc. Jun 19, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $5,625 |
| Csl Behring Oct 3, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $5,610 |
| Biocryst Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee ORLADEYO · Immunology | $3,850 |
| Novartis Pharmaceuticals Corporation Oct 2, 2025 | Consulting Fee | $3,200 |
| Novartis Pharmaceuticals Corporation Dec 23, 2025 | Consulting Fee | $2,800 |
All 70 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 23, 2025 | Consulting Fee | $2,800 |
| Biocryst Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee ORLADEYO · Immunology | $3,850 |
| Eli Lilly and Company Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $8,000 |
| Eli Lilly and Company Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) EBGLYSS · Immunology | $1,600 |
| Eli Lilly and Company Nov 20, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $800 |
| Csl Behring Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $199 |
| Genzyme Corporation Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Biocryst Pharmaceuticals, Inc. Nov 4, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Orlando, FL | $366 |
| Biocryst Pharmaceuticals, Inc. Nov 4, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Orlando, FL | $177 |
| Csl Behring Nov 1, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $1,377 |
| Csl Behring Nov 1, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $24.83 |
| Csl Behring Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $593 |
| Csl Behring Oct 12, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $741 |
| Csl Behring Oct 12, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $593 |
| Csl Behring Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $1,320 |
| Csl Behring Oct 3, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $5,610 |
| Csl Behring Oct 3, 2025 | Travel and Lodging Andembry · Hematology · travel to Oakbrook, IL | $620 |
| Novartis Pharmaceuticals Corporation Oct 2, 2025 | Consulting Fee | $3,200 |
| Csl Behring Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $1,320 |
| Csl Behring Sep 18, 2025 | Travel and Lodging Andembry · Hematology · travel to Oakbrook, IL · in-kind | $490 |
| Csl Behring Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $1,320 |
| Csl Behring Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $673 |
| Csl Behring Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $6.76 |
| Csl Behring Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $990 |
| Pharming Healthcare, Inc. Jun 19, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $5,625 |
| Pharming Healthcare, Inc. Jun 19, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to CINCINNATI, OH · in-kind | $530 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 12, 2025 | Consulting Fee TAKHZYRO · GENETIC DISEASE | $837 |
| Pharming Healthcare, Inc. May 29, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $5,625 |
| Csl Behring May 29, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $1,577 |
| Csl Behring May 29, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $382 |
| Pharming Healthcare, Inc. May 29, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to CINCINNATI, OH · in-kind | $296 |
| Pharming Healthcare, Inc. May 29, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to CINCINNATI, OH · in-kind | $255 |
| Pharming Healthcare, Inc. May 29, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to CINCINNATI, OH · in-kind | $108 |
| Pharming Healthcare, Inc. May 29, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to CINCINNATI, OH · in-kind | $108 |
| Pharming Healthcare, Inc. May 29, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to CINCINNATI, OH · in-kind | $46.00 |
| Pharming Healthcare, Inc. May 29, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to CINCINNATI, OH · in-kind | $36.60 |
| Pharming Healthcare, Inc. May 29, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to CINCINNATI, OH · in-kind | $30.00 |
| Pharming Healthcare, Inc. May 29, 2025 | Travel and Lodging RUCONEST · BIOLOGIC · travel to CINCINNATI, OH · in-kind | $20.93 |
| Takeda Pharmaceuticals U.S.A., Inc. May 28, 2025 | Consulting Fee TAKHZYRO · GENETIC DISEASE | $837 |
| Csl Behring May 20, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $2,032 |
| Csl Behring May 20, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $1,051 |
| Takeda Pharmaceuticals U.S.A., Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) TAKHZYRO · GENETIC DISEASE · in-kind | $1,653 |
| Pharming Healthcare, Inc. May 9, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $2,250 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Consulting Fee | $10,000 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Travel and Lodging travel to EAST HANOVER, NJ | $714 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Travel and Lodging travel to EAST HANOVER, NJ · in-kind | $228 |
| Novartis Pharmaceuticals Corporation May 1, 2025 | Travel and Lodging travel to Whippany, NJ · in-kind | $381 |
| Novartis Pharmaceuticals Corporation May 1, 2025 | Education in-kind | $19.31 |
| Csl Behring Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $714 |
| Csl Behring Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $476 |
| Genzyme Corporation Apr 3, 2025 | Consulting Fee | $2,070 |
| Genzyme Corporation Mar 27, 2025 | Travel and Lodging travel to Cincinnati, OH | $28.00 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 20, 2025 | Consulting Fee TAKHZYRO · GENETIC DISEASE | $1,582 |
| Csl Behring Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $1,359 |
| Csl Behring Mar 19, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology · in-kind | $1,112 |
| AbbVie Inc. Mar 18, 2025 | Consulting Fee | $2,625 |
| AbbVie Inc. Mar 14, 2025 | Consulting Fee | $5,800 |
| AbbVie Inc. Mar 14, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $113 |
| AbbVie Inc. Mar 14, 2025 | Travel and Lodging travel to ATLANTA, GA · in-kind | $84.07 |
| Genzyme Corporation Mar 7, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Mar 2, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Mar 2, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Sanofi-aventis U.S. LLC Mar 1, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 11, 2025 | Consulting Fee TAKHZYRO · GENETIC DISEASE | $550 |
| Adma Biomanufacturing LLC Feb 4, 2025 | Consulting Fee | $18.35 |
| Csl Behring Jan 28, 2025 | Consulting Fee Andembry · Hematology | $7,920 |
| Csl Behring Jan 28, 2025 | Travel and Lodging Andembry · Hematology · travel to Cincinnati, OH | $318 |
| Csl Behring Jan 28, 2025 | Travel and Lodging Andembry · Hematology · travel to Cincinnati, OH | $106 |
| Csl Behring Jan 28, 2025 | Travel and Lodging Andembry · Hematology · travel to Cincinnati, OH | $106 |
| Adma Biomanufacturing LLC Jan 1, 2025 | Consulting Fee | $4.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $405,054 in research payments for these studies, mostly to the institutions running them.
- A multicentre, randomized, double-blind, placebo-controlled, dose find
GlaxoSmithKline, LLC. - A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc. - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation - Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
Csl Behring · Completed · NCT06806657 - Study name not reported
Ionis Pharmaceuticals, Inc. - Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
Csl Behring · Completed · NCT04739059 - CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
Csl Behring · Completed · NCT05819775 - (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Sanofi US Services Inc. · Recruiting · NCT04910685 - A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis …
Amgen Inc. - A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.